MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.540
+0.030 (1.99%)
At close: Dec 12, 2025, 4:00 PM EST
1.520
-0.020 (-1.30%)
Pre-market: Dec 15, 2025, 7:10 AM EST
MediciNova Revenue
MediciNova had revenue of $123.32K in the quarter ending September 30, 2025.
Revenue (ttm)
$257.92K
Revenue Growth
n/a
P/S Ratio
292.89
Revenue / Employee
$19,840
Employees
13
Market Cap
75.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 4.04M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 6.00M | 5.20M | 647.99% |
| Dec 31, 2012 | 802.58K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 263.88K | -540.19K | -67.18% |
| Dec 31, 2005 | 804.07K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MNOV News
- 7 days ago - MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - GlobeNewsWire
- 27 days ago - MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor - GlobeNewsWire
- 5 weeks ago - MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards - GlobeNewsWire
- 6 weeks ago - MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication - GlobeNewsWire
- 2 months ago - MediciNova to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire
- 3 months ago - MediciNova Provides Shareholder Update on Key Developments - GlobeNewsWire
- 3 months ago - MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial - GlobeNewsWire